Publication | Closed Access

Empagliflozin monotherapy with sitagliptin as an active comparator in patients with type 2 diabetes: a randomised, double-blind, placebo-controlled, phase 3 trial

Diabetes ManagementCardiovascular DiseaseMedicineDiabetesActive ComparatorType 2PharmacotherapyDiabetes MellitusEmpagliflozin MonotherapyPharmacologyAnticoagulant